Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock () or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

National Institute of Allergy and Infectious Disease
NIH 3D
FAQsBioArt

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock () or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

NIH3D

Talazoparib

PubChem 135565082
was used by NIH 3D workflows to automatically generate models for
buffavaholic
Created:
10/27/20
Submitted:
3/6/23
Published:
3/6/23
ball and stick, print caution
135565082-bas-color-print_NIH3DAtoms shown as ball-and-stick with standard colors. 3D printable, with caution, using certain 3D printers.

Select an image below to view

ball and stick, print cautionsticks, not intended for 3D printingsticks, not intended for 3D printingsticks, print cautionspace-filled, print cautionsticks, print cautionspace-filled, print cautionball and stick, print caution
3DPX-015007

NIH 3D DOI:

https://doi.org/10.60705/3dpx/15007.2

Licensing:

CC-BY
How to cite this NIH 3D entry
56
1
Version 2

Category

Small Molecules
Small Molecules
Description
Talazoparib was approved by the FDA for use in germline BRCA mutated, HER2 negative, locally advanced or metastatic breast cancer on October 16, 2018 under the trade name Talzenna. Talzenna was granted approval based on the results of the EMBRACA trial in which talazoparib resulted in a mean 8.6 months progression-free survival time versus physician's choice chemotherapy which resulted in 5.6 months progression-free survival.
Source Data Details
https://pubchem.ncbi.nlm.nih.gov/image/imagefly.cgi?cid=135565082&width=400&height=400
https://pubchem.ncbi.nlm.nih.gov/image/imagefly.cgi?cid=135565082&width=400&height=400